A Multi-Omics Approach for Novel Drug Targets, Biomarkers and Risk Algorithms for Myocardial Infarctionbroad
TargetMI · Horizon Europe grant · 2023-10-01–2028-09-30
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2022-PATHFINDERCHALLENGES-01 · scheme HORIZON-EIC · topic HORIZON-EIC-2022-PATHFINDERCHALLENGES-01-03. CORDIS record →
Objective
In TargetMI we propose a high throughput multi-omic approach for rapid discovery of novel drug targets, biomarkers and risk algorithms, applied here to atherosclerosis, myocardial infarction (MI) and their risk factors. Cardiovascular disease is a major cause of death and morbidity worldwide. The causes of MI are highly complex involving genetic, lifestyle and environmental factors. Whilst much research effort has been invested in attempting to decipher these factors, clinical applications of findings are disappointingly few. We will harness four -omic datasets (whole genome, transcriptomic, metabolomic and proteomic data) on 1000 highly phenotyped samples of the Maltese Acute Myocardial Infarction (MAMI) Study. These were collected from cases, controls and relatives of cases (including 80 families) with meticulous attention to preanalytical variables. We will identify intermediate phenotypes associated with risk of MI and its associated risk factors. Using a combination of approaches including extreme phenotype and family-based approaches we will identify variants which robustly influence these intermediate phenotypes. The genes thus identified are potential drug targets that influence risk of MI via an intermediate phenotype and are applicable across all populations. They will be validated through various approaches including computational analysis, (using Mendelian randomisation and 10 year follow-up data), and functional work that includes using zebrafish as an animal model. Machine learning algorithms will be used to analyse the multi-layered data to identify novel biomarkers and risk algorithms, including polygenic risk scores, for early risk prediction in the clinic. Quantitative targeted proteomic assays will be developed for further validation in other cohorts facilitating clinical use. Besides the increase in knowledge on the molecular etiology of MI, this powerful integrated strategy will bring rapid clinical translation of unprecedented multi-omic data.
Beneficiaries (2)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| UNIVERSITA TA MALTA | MT | coordinator | €3,179,815 | |
| ACADEMISCH ZIEKENHUIS LEIDEN | NL | participant | €820,025 |
Get the EU Defence Funding Calendar — free
The full calendar of open EU defence and dual-use funding calls, sorted by deadline, updated nightly. Delivered with DFM Analysis, our weekly briefing on who is funding what in European defence.
Or browse all open defence & dual-use calls on the funding calendar →
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; the paid Annual Professional subscription is handled on DFM Analysis.